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Abstract: This review supplies the reader with a detailed overview on the utilization of intramolecular processes  
for a design and synthesis of prodrugs. It is well known that a respected number of drugs suffer from low bioavail- 
ability, toxicity, unpleasant taste and presystemic first-pass metabolism which result in drug inactivation. The clas- 
sical prodrug approach in which the linkage attaching the parent drug to its non-toxic linker and cleaved by in vivo  
enzyme’s catalyzed reactions has proven its success in solving toxicity and bioavailability related issues. On the  
other hand, prodrugs based on chemical interconversion in which the prodrug releases the corresponding active  
parent drug via inter or intramolecular chemical process in the absence of an enzyme is considered as a better  
alternative approach since the prodrug cleavage is not dependent in the efficiency or quantity of the enzyme catalyzes the interconversion  
of the prodrug. Examples of successful prodrugs using the chemical approach via intramolecular processes such as cyclization reactions  
are illustrated as well.  
In addition, another part of this review is devoted to cover reported studies on enzyme models and their utilization for the design and syn-
thesis of a variety of novel prodrugs. In this approach, computational calculations using DFT and MM methods were exploited and corre-
lations between experimentally determined and computed values of the rate-limiting step in the studied intramolecular processes were 
utilized in the prodrugs design. Selected examples of the designed prodrugs include aza-nucleosides for the treatment of myelodysplastic 
syndromes, the anti-Parkinson’s agent dopamine, the anti-viral acyclovir, the anti-malarial atovaquone, and statins for lowering choles-
terol levels in the blood, the antihypertensive atenolol, the antibacterial cefuroxime, the anti-bleeding tranexamic acid, the decongestant 
phenylephrine, and the pain killer paracetamol.  
Keywords: Intramolecular, cyclization, prodrug, trimethyl lock, intramolecular Activation, Quantum Mechanics Calculations, lactonization 
cyclization. 
1. INTRODUCTION 
The development of prodrugs has the potential to overcome 
many pharmacokinetics barriers. For example, several drugs un-
dergo first pass metabolism which leads to drug inefficiency and 
poor bioavailability, and sometimes to toxicity. The classical pro-
drug approach by which the linkage attaching the active parent drug 
to a non-toxic linker and cleaved by enzyme’s catalyzed reactions 
has proven its success in solving toxicity and bioavailability related 
issues. On the other hand, prodrugs based on chemical interconver-
sion by which the prodrug releases the corresponding active parent 
drug via inter or intramolecular process without the involvement of 
enzymes is considered as a better alternative approach since it does 
not have inter- and intra-individual variability (differences in the 
quantity and efficiency of the metabolic enzyme) that might affect 
the efficiency of the metabolic enzymes. 
Among the most studied activation strategy in the prodrug 
chemical approach is cyclization elimination reactions that have 
been used in providing many prodrugs from analgesics to HIV pro-
tease inhibitors [1]. 
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2. INTRAMOLECULAR ACTIVATED ESTER PRODRUGS 
One of the problems that drugs may suffer is a lack of specific-
ity for their target. The prodrug approach was successful in over-
coming this problem and improving the delivery of drugs to their 
targets, especially for ester prodrugs, involving substitution of car-
boxyl and hydroxyl groups of their active drugs, which are readily 
hydrolyzed in vivo, either by chemical or enzymatic means to pro-
vide their active drugs [2].  
Drug delivery can be improved by modulating the drug’s 
physiochemical properties which affect their absorption and deliv-
ery to various membranes and tissues. The prodrug approach by 
which the activation is catalyzed by enzymes is useful for parent 
drugs containing hydroxyl or carboxyl groups. On the other hand, 
phenol esters when activated by metabolic enzymes provide the 
corresponding active drugs in fast rates, whereas, amides show little 
chemical reactivity towards enzyme’s activation. Therefore, in-
tramolecular activated amide prodrugs had been considered as an 
alternative approach for enzymatic activation that bypasses inter- 
and intra- individual variability that might affect the metabolism by 
enzymes. In addition, this approach provides a fine tuning of the 
cleavage rate of the prodrug which can be accomplished by select-
ing the functional groups involved in the cyclization process.  
An example for such approach is the pilocarpine prodrugs 
based on diesters of pilocarpic acid. These prodrugs upon in vitro 
and in vivo administration (eliminate comma) undergo specific 
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base- catalyzed cyclization to pilocarpine which consists of a first 
step by which hydrolysis of the ester yields a hydroxyl which acts 
as a nucleophile and attacks the phenyl ester group that initiates for 
cyclization to finally give the parent drug, pilocarpine (Fig. 1) [3]. 
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Fig. (1). Cyclization of diester of pilocarpic acid to release pilocarpine, 
R=H, R’ = OH. 
The prodrug approach has been utilized to enhance the ocular 
delivery of pilocarpine. 
A number of lipophilic alkyl and aryl alkyl esters of pilocarpic 
acid were synthesized and evaluated as prodrugs of pilocarpine. 
The results obtained suggested that the pilocarpic acid esters may 
be potentially useful prodrugs with enhanced drug delivery and 
bioavailability properties, especially when further derivativized to 
give non-labile, easily formulated pilocarpic acid diesters that are 
readily converted to the active parent drug, in vivo. In aqueous solu-
tion the ester prodrugs undergo a quantitative and apparent specific 
base-catalyzed lactonization to pilocarpine. 
The diester prodrugs were of special interest, since they com-
bine an enhanced bioavailability and greatly prolonged duration of 
action with high stability in eye drops formulations for the treat-
ment of glaucoma. The corneal permeability of pilocarpine is in-
creased by the prodrug derivatives. 
Several monoesters were capable of maintaining durations of 
action of 1.5 times longer than that of pilocarpine while the diesters 
were active for up to 2.25 times longer [4].  
Some of the lipophilic pilocarpine prodrugs exhibit amphiphilic 
properties, which may contribute to the ocular irritation of these 
compounds [5]. 
?-Amino acid prodrugs of camptothecins (CPTs) are another 
example of intramolecular ring closing activation. The camptothe-
cin ester prodrugs converted to their active lactones by intramoleul-
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Fig. (2). A mechanism for the conversion of camptothecin ?-amino acid esters to their carboxylates. R2= H or CH3, R3= H or TBS, R4= H or OH. 
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car cyclization reaction that is preferable over hydrolysis followed 
by intramolecular cyclization reaction at pH 7.4 [6]. 
Camptothecins are antitumor agents that work on S-phase by 
binding to the topoisomerase and I-DNA complex during DNA 
replication causing double strand breaks and cell death (Fig. 2) [6].  
?-Amino acid ester prodrugs reactivity is relatively high due to 
the fact that at pH values below the their pKa values their amino 
terminal is positively charged. Recently, an alternative route that 
facilitates the production of reactive lactone from camptothecin ?-
amino acid ester prodrugs was suggested as shown in Figure 3 [6]. 
The most common problem associated with CPT is the instabil-
ity of the 20-hydroxy lactone, which is easily hydrolyzed at neutral 
pH to yield the inactive carboxylate anion. It was shown that both 
the lactone ring stability and the 20-hydroxy group of CPT are criti-
cal for its antitumor activity. Further, it was demonstrated that 
masking the 20- hydroxyl group of CPT, results in reduced activity 
of the drug and increased stability of the lactone ring. The hydroxyl 
in position 20 generates an intramolecular hydrogen bond with the 
carbonyl moiety of the lactone, which accelerates the hydrolysis of 
the otherwise stable lactone ring. Therefore, masking this hydroxyl 
by a chemical linker that can be selectively removed, is a conven-
ient approach for a generation of CPT prodrug [7]. 
In addition, cytotoxicity studies performed with several cancer 
cell lines clearly demonstrated a significant reduce in toxicity of the 
prodrugs of CPTs compared with their active parent drug [7].  
2.1. Prodrug Activation Via Diketopiperazine Formation 
Dipeptides as carriers for delivering parent drugs via non-enzymatic 
pathway (formation of DKP) have been suggested as good candi-
date to deliver drugs to their target sites. Dipeptides are carriers 
used to optimize drug delivery especially for hydroxyl-containing 
drugs. Dipeptide esters of paracetamol (Figure 4) have shown to 
undergo hydrolysis to the corresponding parent drug and DKP at 
pH 7.4 and temperature of 37˚C. Higher half-life values were ob-
served with C-terminal bulky amino acids.  The latter is believed to 
cause the peptide linkage to reside in the cis form, which is easily 
can cyclize to a DKP, thus leading to very reactive substrates. He-
patotoxic effects of paracetamol was decreased or even eliminated 
by paracetamol esterification with dipeptides [8]. 
The esterification approach of paracetamol with amino acids 
was proposed to obviate the sever hepatotoxicity of the drug at high 
doses as well as to increase its aqueous solubility [8]. 
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Fig. (4). Paracetamol esterification with dipeptides, R1 = R2 = H 
2.2. Coumarin-Based Prodrug System 
Prodrugs of amine and alcohol containing drugs based on cou-
marin derivatives as a linker with low toxicity have been developed 
in order to increase the bioavailability and reduce the toxicity of 
certain drugs. This approach was advocated by Wang and co-
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Fig. (3). An alternative route in which camptothecin prodrugs convert to their active lactones. R2= H or CH3, R3= H or TBS, R4= H or OH. 
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workers and is based on the fact that coumarin derivatives attached 
to active drugs undergo a rapid lactonization at a physiological 
environment of pH 7.4 (Fig. 5). 
The coumarins are of great interest due to their biological prop-
erties. In particular, their physiological, bacteriostatic and anti-
tumor activity makes these compounds attractive for further back-
bone derivativisation and screening as novel therapeutic agents. 
Weber and co-workers have shown that coumarin and its metabolite 
7-hydroxycoumarin have antitumor activity against several human 
tumor cell lines. Both coumarin and coumarin derivatives have 
proved to be potential inhibitors of cellular proliferation in various 
carcinoma cell lines. In addition it has been shown that 4-
hydroxycoumarin and 7-hydroxycoumarin inhibited cell prolifera-
tion in a gastric carcinoma cell line [9]. 
One example for such approach is coumarin based prodrug of 
DADLE (H-D-Leu-Phe-Gly- D -Ala-Tyr-OH) which is capable to 
undergo cyclization after hydrolysis catalyzed by esterases. This 
prodrug releases the active drug after incubation in the plasma or 
with porcine liver esterase.   
One unique feature of this prodrug system is that the final product 
of the promoiety is coumarin, the toxicity of which has been exten-
sively studied. Coumarin was found to be relatively nontoxic. The 
known toxicity profile of coumarin clears one major hurdle in de-
veloping a generally applicable prodrug system [10]. 
2.3. Propranolol Prodrugs 
Propranolol is a sympatholytic nonselective beta blocker. It is 
used to treat high blood pressure, a number of heart dysrhythmias, 
thyrotoxicosis, and essential tremors. It is used to prevent migraine 
headaches, and to prevent further heart problems in those with 
angina  previous heart attacks. Propranolol highly variable and low 
oral bioavailability due to high first pass metabolism. Therefore, the 
prodrug approach was used to reduce the extensive effect of the 
liver on the propranolol before reaching the systemic circulation.   
A cyclic oxazolidinones derivative and esters of propranolol (7) 
have also been investigated as good and novel prodrug candidates 
[11].  
There are 3 possible different mechanisms for the degradation 
of propranolol prodrugs [11]: 
(a) a mechanism that involves an intra-nucleophilic attack of 
the free amine group on the carbonyl of the ester group, (b) a 
mechanism consists of a nucleophilic attach of a water molecule on 
the carbonyl ester group catalyzed by a base (free amine group) (c) 
a mechanism by intramolecular general acid (protonated amine) 
catalysis in which a hydroxyl ion attacks the carbonyl ester. Both 
mechanisms (b) and (c) are hydrolysis processes that yield propra-
nolol whereas, mechanism (a) represents an intramolecular ami-
nolysis giving rise to the formation of stable N-acylated propranolol 
derivatives (Fig. 6). 
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Fig. (6). Mechanisms (a), (b) and (c) for the degradation of propranolol 
prodrugs with increasing the pH to >7 the aminolysis becomes predominant. 
Figure 7 illustrates seven different esters that were synthesized 
and studied with the aim to investigate the kinetics of their degrada-
tion in aqueous solution and in human plasma which might reflect 
the behavior of propranolol prodrugs in such media.  This discrep-
ancy between the different esters might be related to steric hin-
drance of the tert-butyl group that hinders the nucleophilic attack 
taking place in the O?N acyl transfer reaction. At pH > 11.5 the 
main reaction of esters 2-6 is intramolecular aminolysis.  
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Fig. (7). Propranolol prodrugs and similar other esters 1-7. 
 
Fig. (5). Coumarin based prodrugs. 
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At pH 7.2 the O ?N acyl transfer reaction of the propranolol 
esters is < 7% of the reaction yield. Similar alkyl esters of timolol 
(8) (Fig. 8) were found to be completely hydrolyzed in aqueous 
media.  
The presence of the bulky tertiary butylamino group in timolol 
esters is the main cause for steric hindrance that limits the ability of 
these esters to undergo intramoleuclar aminolysis. At pH 7-10, 
propranolol esters have showed greater tendency to hydrolyze than 
to undergo intramolecular aminolysis. The predominant factor that 
determines the mode of the reaction whether to proceed with hy-
drolysis or intramolecular aminolysis mechanism is the bulkiness of 
the amine moiety in the esters of ?-aminoalcohols. Another factor 
that affects the ratio hydrolysis vs. aminolysis is the steric proper-
ties within the structure, as it is seen with the low tendency of the O 
-pivaloyl ester (5) to react via aminolysis compared to alkyl esters 
2-4 (Fig. 8).  
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Fig. (8). Timolol ester 8. 
Timolol prodrugs are more lipophilic than their active parent 
drug, timolol, thus their permeation through the cornea is higher 
than their parent drug. Timolol ester prodrugs increase timolol con-
centration in aqueous humor and decrease timolol systemic concen-
tration by 10 fold. Additionally, they increase the therapeutic index 
of timolol by 15-fold and also showed prolonged duration of action 
[12]. 
Moreover, various aliphatic esters of timolol, a non-selective P-
adrenergic receptor blocker, have been developed as prodrugs to 
potentially diminish the systemic absorption and therefore side-
effects of topically applied timolol through increased corneal ab-
sorption [2]. 
2.4. Cyclization-Elimination Due to a Carboxylate Group 
Intramolecular cyclizations are not restricted to attack by nu-
cleophilic nitrogen (basic amino or acidic amido group). They can 
also be catalyzed by nucleophilic oxygen, as in a carboxylate group, 
a phenol or an alcohol. These reactions can also be proceeding by 
catalysis of nucleophilic oxygen (phenol or an alcohol) such as the 
hemiester prodrugs of phenol or paracetamol shown in Figure 9. 
Three different mechanisms were proposed for these hydrolysis 
reactions: acid- catalyzed, base-catalyzed, and an intramolecular 
nucleophilic process resulting in a cyclization elimination reaction 
(Fig. 9). In buffer solutions, the mechanism is pH dependent. At pH 
7.4 and 37° C, the cyclization- elimination reaction was the domi-
nant, with t? of 1 - 350 minutes. The number of promoiety substitu-
ents and their shape and the pKa of the phenol derivative influence 
the reactivity of these prodrugs. The reactions of the succinate es-
ters at this physiological pH were about 150 times more potent than 
their corresponding glutarate esters. In addition, it was found that 
branching with methyl of the promoiety (X= CH2CH(CH3)CH2) 
has increased the reactivity of the ester. The cleavage rate for 
paracetamol esters (R = NHCOCH3) was found to be 2-fold higher 
than that of phenol esters (R = H). Generally, no or little enzyme’s 
activity was seen in human plasma. This is in accordance with the 
fact that hemiesters are known to be inert towards cholinesterase 
enzyme [13]. 
2.5. Two Step Activation Prodrugs   
2.5.1. General 
In two-step activation of prodrugs the nucleophile is formed in 
situ. Otherwise, it remains until the prodrug undergoes cleavage by 
metabolism. Examples for such nucleophile are a phenol or an al-
cohol masked with a carboxylate ester. These kinds of prodrugs 
release the corresponding active parent drugs via enzymatic and/or 
nonenzymatic hydrolysis of their ester moiety which is followed by 
an intramolecular nucleophilic attack. 
An example for such approach is pilocarpine prodrugs that 
aimed at improving ocular delivery (Figure 1). These prodrugs are 
pilocarpic acid diesters characteristic with high lipophilicity. The 
first activation step is removing the acetyl linker by an enzymatic 
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Fig. (9). Mechanism of carboxylic acid hydrolysis, X=CH2CH(CH3)CH2,  CH2CH2CH2,CH2C(CH3)2CH2, R=H or NHCOCH3. 
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hydrolysis of ester which is followed by a second step in which an 
intramolecular nucleophilic attack is leading to a loss of the alcohol 
linker and to a ring closing to yield pilocarpine [14]. 
p-Acetamidophenol amino acid esters (Figure 10) have been 
suggested as useful and efficient prodrugs for p-acetamidophenol. 
Stability and solubility in water for these prodrugs can be achieved 
by selecting the appropriate amino acid group with the desired hy-
drophilic lipophilic balance value (HLB value) [13].  
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Fig. (10). p-acetamidophenol amino acid esters. 
Investigations have shown that the pH-rate profile for ester 12 
hydrolysis (Fig. 10) is totally different from that of esters 10 and 
11. At pHs above the pKa of the carboxyl group of 12 its decompo-
sition rate was found to be unaffected by the pH of the medium and 
the concentrations of the zwitterions 12a or the anion 12b were 
essentially constant (Fig. 11). This phenomenon can be attributed to 
the fact that the dominant reaction is intramolecular involving the 
zwitterion of 12 (12a) at pH 2-6 and its anion (12b) when the pH of 
the medium is 6 - 11.  
At pH values slightly above the pKa of the carboxyl group of 12 
(between pH 2 and 10), the hydrolysis of 12 is subjected to in-
tramolecular nucleophilic catalysis, and its rate value is higher than 
that of ester 10. The main hydrolysis of aliphatic alcohol esters is 
intermolecular reaction such as in the case of esters of ?- and ? -
aspartic acid and the intramolecular hydrolysis is rarely occurring. 
The ethanolic esters of ? -aspartic acid undergo slower hydrolysis 
than the glycinate esters and the shapes of the pH-rate profiles for 
the three systems are similar [13].  
2.5.2. Therapeutic Advantages of Amino Ester Prodrugs 
Amino acid ester prodrugs of the dopamine D2 agonist 5-OH-
DPAT L-valine and ?-alanine prodrugs of 5-OH-DPAT may meet 
the requisites for improved transport across the skin by iontophore-
sis for treatment of Parkinson disease [15]. 
Most striking effect was observed with the levels of glutathione, 
GSH, as the glycine-acetaminophen prodrug significantly protected 
the depletion of GSH when compared to its parent drug. Glycine-
acetaminophen prodrug showed remarkable potential in the field of 
gastric and hepatic complications [16]. 
An ester prodrug approach for NSAID’s by which the carboxyl 
group of the NSAID is blocked is another approach to reduce the 
GI toxicity associated with NSAIDs without affecting their activity. 
Because of the low toxicity of the amino acids, they are considered 
the best choice to be utilized as linkers for NSAIDs prodrugs. For 
example, the basic ?-amino group such as in prodrug 13 (Figure 12) 
was found to enhance the water-solubility of the parent drug (Fig-
ure 12), however, it decreased the chemical stability. It is believed 
that such behavior is a result of the presence of the protonated 
amine group which enhances water solubility whereas the accelera-
tion in the hydrolysis rate of the prodrug is mainly due to the unpro-
tonated amine group which serves as a nucleophile resulting in 
intramolecular rearrangement of the prodrug to yield the amide 
drug.  However, a number of prodrugs containing a secondary car-
bamate such as 14 (R1 = R2 = H), tend to form the corresponding N 
acylamine via a rearrangement process (Fig. 13). This rearrange-
ment process is inhibited by the presence of bulky amino acids such 
as Phe or Val and a carrier such as N- methyl glycine (sarcosine). 
Figure 12 illustrates a number of aminocarbonyloxymethyl deriva-
tives of flufenamic acid and diclofenac containing amino acid am-
ides as carriers. This carrier replacement decreases the carbamate 
pKa in 1.2 units and therefore it inhibits the O?N rearrangements 
when compared with 14. 
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Fig. (12). Chemical structures of amino acid ester 13 and amino acid amides 14 and 15. 
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Fig. (11). p-Acetamidophenol amino acid esters. 
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Fig. (15). N-Mannich basses of salicylamide. 
The differences in the pKa and bulkiness of the terminal amino 
acid amide and ester groups lead to a large difference in the chemi-
cal reactivity of both amino acid ester 13 and amide 14 [17].  
In this approach, the prodrug is intraconverted to its active par-
ent drug by an intramolecular cyclization-elimination and the in-
termolecular cleavage of the ester bond by hydrolysis is not ob-
served. By this approach, the prodrug releases its corresponding 
active parent drug in rates that are solely determined by the in-
tramolecular ring-closing reaction.  
Studies have shown that carbamate prodrugs of alcohols such as 
19 undergo cyclization reactions in slower rates than carbamate 
prodrugs of phenols such as 16 (Fig. 14) [18]. On the other hand, 
N-Mannich bases of salicylamide (Fig. 15) as prodrugs for amines 
undergo cleavage into their corresponding parent drugs in much 
slower rates than their corresponding N-Mannich bases of alkyl 
amides (Fig. 15) [17].  
2.6. Basic Esters 
Basic esters are esters involving a basic group in their alkyl part 
or in their acyl moiety and are considered important for the prodrug 
approach. These esters are characterized with good water solubility 
and are ready to be chemically hydrolyzed at physiological pH.  In 
addition, their binding to carboxylesterase is very weak. Examples 
for such compounds are the amino esters (compounds 22-24 in Fig. 
16) which their hydrolysis rates are largely affected by steric ef-
fects. 
For instance, a study has showed that aryl esters of 2-
aminocarboxylic acid such as compound  23, 4- nitrophenyl 2-
aminocyclohexanecarboxylate, aryl = 4-NO2-C6H4, Figure 16) 
underwent hydrolysis in pH 7 in higher rates than their correspond-
ing lacking the amine moiety [19].  
Various promising applications of ?-amino acid esters have 
been published in recent years, such as valaciclovir, the L-valyl 
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Fig. (13). Rearrangement of prodrugs such as 14 in pH 7.4 to yield N-acylamine. 
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Fig. (14). Carbamate prodrugs 16 and 19 and their cleavage reactions to phenol 17 and alcohol 20, respectively.  
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ester of acyclovir, anti-viral agent, which showed encouraging 
pharmacokinetic results in the rat and monkey. For example, there 
was significant improvement in the oral bioavailability of acyclovir 
using the prodrug approach over the limited bioavailability of the 
drug itself. Interestingly, the rat liver enzyme that hydrolyzes 
valaciclovir, showed high selectivity for various amino acid esters 
of acyclovir, differently from typical esterases and peptidases. Re-
cently, the L-aspartate ?-ester, and L-lysyl and L-phenylalanyl es-
ters of acyclovir were prepared and examined as prodrugs for nasal 
absorption. The aspartate ? -ester was the most stable, and was also 
the only one to be detectably absorbed, seemingly by active uptake 
[19]. 
COORH2N
O
OAryl
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+
H
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+
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23 24
22
 Trans-4-(aminomethyl) cyclohexanecarboxylates
 
Fig. (16). Hydrolysis of basic esters, R=aryl or aryl methyl. 
3. AMIDE PRODRUGS 
Prodrug design has been used to improve physicochemical 
characteristics of amine drugs, by improving the metabolic stability 
and decreasing ionization of the amine parent drugs resulting in 
improvement of its membrane penetration. Intramolecular cycliza-
tions have been proposed to release the parent drug [2]. 
Vigroux and coworkers reported the synthesis of mutual pro-
drugs of benzoxazolones and oxazolidinones. In the cases of pro-
drugs of chlorzoxazone, 6-benzoylbenzoxazolone and 5-benzoyl-
benzoxazolone with paracetamol, the activation of these prodrugs 
involves cyclization reaction that is independent on enzymes ca-
talysis (Fig. 17). While the activation of prodrugs of oxazolidinones 
(metaxaloned and mephenoxalone) with paracetamol involve two 
steps, the first depends on plasma enzymes to form the intermediate 
2-hydroxypropyl isocyanate, which is then converted spontaneously 
by intramolecular cyclization to the active oxazolidinones drugs 
(Fig. 18) [20]. 
Fredholt and Bundgaard synthesized and studied 13 phenyl car-
bamate prodrugs to determine the effect of R1, R2 and R3 on the rate 
of intramolecular regeneration of the parent phenol (Figure 19) 
[21]. They concluded that when R1 is hydrogen the rate is much 
higher than when it is methyl or ethyl. Bulky R2 groups decreased 
the reactivity of these prodrugs since the amide attack on the car-
bamate becomes difficult, while increasing the polarity of R2 group 
increased the prodrug reactivity. The decrease in the pKa of R3 in-
creases the intramolecular cyclization rate by making the phenolate 
ion a better leaving group [21]. Carbamate prodrugs were further 
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Fig. (17). Intramolecular activation of benzoxazolones prodrugs: chlorzoxazone, X = 5-Cl; 6-Benzoylbenzoxazolon, X= 4-benzyl; 5-benzylbenzoxazolone, X= 
5-benzyland R= paracetamol in all three prodrugs. 
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Fig. (18). Intramolecular activation of oxazolidinones prodrugs: metaxalone, X = 3, 5(Me)2;mephenoxalone, X = 2-OMe;R= paracetamol in both prodrugs. 
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studied using phenol as a model for phenol containing drugs having 
low bioavailability due to first pass metabolism. A Study of 9 com-
pounds with different substituents at the nitrogen atoms (Fig. 20) 
demonstrated that the carbamate prodrugs were stable in acidic 
conditions and were not affected by liver or plasma enzymes. While 
the rate of intramolecular cyclization was not affected by enzymes 
it was greatly influenced by the steric effect of the substituent 
groups at the amine nitrogen [22]. 
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Fig. (20). Chemical structure of  phenyl -N-(2- aminoethyl) carbamates. 
Basic carbamate prodrugs were developed in which the mecha-
nism of the release of the parent drug is intramolecular and not 
enzymatic (Fig. 15). A study on these prodrugs confirmed that 4- 
hydroxyanisole is formed by cyclization and that the nonprotonated 
amine is essential for the reaction, which is fast at pH 7.4 compared 
to lower pHs. This difference in reaction rates is dependent on the 
environmental pH and structure and can be utilized for the devel-
opment of prodrugs [18]. 
Doxorubicin hydrazone and hydrazine carboxylate prodrugs 
were developed in order to be targeted to tumors. Hydrazine car-
boxylate and hydrazone designed to be linkers between doxorubicin 
and a polymer. The study of these prodrugs confirmed that the 
product of cyclization is due to intramolecular reaction in which the 
hydroxyl on C14 attacks the carbonyl group in the hydrazone (Fig. 
21) [23]. Activity of the cyclization product has not been studied 
neither in vivo nor in vitro, since doxorubicin itself is ineffective in 
inhibition of tumor growth rate in murine B16F10 melanoma ani-
mal model without a carrier [24]. It is expected that this conjugate 
will be less active than doxorubicin and the free doxorubicin will 
not be highly active [23]. 
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Fig. (21). Intramolecular cyclization of doxorubicin prodrug. 
Prednisolone prodrug was designed as prednisolone 21-
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Fig. (19). Carbamate prodrugs activation. 
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tramolecularly to prednisolone (Fig. 22). The rate of the reaction is 
increased with an increase in the pH. This indicates that the nucleo-
philic amide group attacks the ester group and causes the release of 
prednisolone [25].  Prednisolone succinate ?-cyclodextrine prodrug 
was also synthesized and studied in vitro, this prodrug showed 
slower hydrolysis compared to the prednisolone succinate ?-
cyclodextrin, therefore it was used for in vivo studies.  In vivo stud-
ies in irritable bowel syndrome rat model indicated that Predniso-
lone succinate ?-cyclodextrine alleviated systemic side effects, 
since the amount of prednisolone absorbed from the upper gastroin-
testinal tracts was much smaller than that absorbed when predniso-
lone administered orally alone. In addition, this prodrug also main-
tained the therapeutic anti-inflammatory effects [26]. 
4. INTRAMOLECULAR ACTIVATION OF WATER-
SOLUBLE PRODRUGS OF HIV-PROTEASE INHIBITOR 
A strategy of water soluble prodrugs of HIV-protease inhibitor 
was developed to release the active parent drug via an intramolecu-
lar process [2, 27, 28].  
These prodrugs have two useful unites, a water solubilizing 
group and self-cleavable spacer, which are linked in tandem to the 
parent drug (Fig. 23). The intraconversion of these prodrugs to their 
active drugs is via a chemical degradation at the spacer. This cleav-
age is based on intramolecular cyclization-elimination involving the 
formation of an imide formation upon exposure to physiological 
environment [2, 27, 28].  
A number of water-soluble KNI-727 prodrugs having different 
conversion times (4 minutes to 34.3 hours) were synthesized by 
structural alteration on the solubilizing moiety (Fig. 24) [2,28]. It 
was found that introducing bulky cyclic tertiary amines with differ-
ent electronic properties (25a-c in Fig. 25) enhanced the intracon-
version, due to the fact that bulky cyclic structures force the tert-
amino group into a suitable conformation for a proton abstraction 
on the neighboring-group rather than providing a steric hindrance 
[1]. It was reported that the half-life value of compound 25a is 
about 10 times higher than that of prodrug 25b, which could be 
explained by the high electron- inductive effect that might be 
caused by the morpholine oxygen. Furthermore, introduction of 
propyl morpholine (25c) displayed a further increase in the half-life 
value because an addition of methylene increases the electron do-
nating effect. Possibly more difficult to make six membered transi-
tion state for deprotonation compared to five membered TS which 
would be more plausible for increasing half-life (Fig. 24) [1, 28]. 
In addition, It was demonstrated that an increase in the water 
solubility of these prodrugs resulted in improvement of their gastro-
intestinal absorption.  
It was found that the biological activity of the AZT-KNI pro-
drug was 920 and 62 times more potent than that of KNI-727 and 
AZT, respectively [1, 28]. 
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Fig. (22). Intramolecular hydrolysis mechanism for prednisolone 21-hemisuccinate ?-cyclodextrin, CYD = cyclodextrin, PD = Prednisolone. 
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Fig. (24). Activation of water-soluble prodrugs of KNI-727, 25a-c via Intramolecular process. 
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Fig. (23). A strategy of water soluble prodrugs that provide the active parent 
drug via an intramolecular reaction. 
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A number of promoieties connecting the hydroxyl of KNI-727 
to 3-azido-3-deoxythimidine (AZT) were also studied by the same 
research group. Under mild alkaline conditions, these linkers were 
found to provide the active parent drug, KNI-727, through in-
tramolecular cyclization involving an imide formation (Fig. 25) [29, 
30]. 
5. THE ACTIVATION OF BIOREDUCTIVE PRODRUGS 
THAT UNDERGO INTRAMOLECULAR CYCLIZATION 
FOLLOWING CHEMICAL REDUCTION 
Hypoxia appears to be a popular and unique feature of cells in 
solid tumors [31-36] and it has been reported to exist in a variety of 
other diseases [31]. Bioreductive prodrugs were designed to selec-
tively target the hypoxic cells in malignant tumors and release cyto-
toxic species after metabolic reduction [31-36]. This section will 
focus on the activation of bioreductive prodrugs that undergo in-
tramolecular cyclization following chemical reduction. 
The three main classes of bioreductive drugs are quinones, N-
oxides and hetero-aromatic nitro groups. However, activation of 
bioreductive prodrugs that undergo intramolecular cyclization fol-
lowing chemical reduction has only tested with nitroaromatic and 
quinone compounds [33, 36]. 
5.1. Quinone as Bioreductive Prodrugs Targeting the Hypoxic 
Cells in Tumors  
An early approach for hypoxia-selective delivery agents is the 
one utilized the quinone propionic delivery agent; the benzoquinone 
proceeds as a trigger and the propionic carrier works as the linker 
while a trimethyl lock provides the steric hindrance necessary to 
optimize a ring closure [37, 38]. Steric hindrance arises from the 
methyl groups (termed ‘trimethyl lock’) has been represented to 
greatly enhance lactonization processes [39, 40]. Metabolic reduc-
tion of the benzoquinone triggers intramolecular cyclization to gen-
erate a lactone and release the drug (Fig. 26) [41].  A comprehen-
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Fig. (25). Conversion of double-drug to KNI-727 and AZT via intramolecular cyclization. 
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Fig. (26). Bioreductive delivery of quinone propionic delivery system. 
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sive study of the trimethyl lock facilated lactonization has been 
represented [39]. 
Prodrug 27 was developed to release the parent drug 26 after a 
reduction of the quinone system under hypoxic conditions, followed 
by formation of bioreduction product (lactone) 28 and a release of 
the parent drug, melphalan methyl ester; MME, 26 (Fig. 27) [33, 
42-43]. 
Upon chemical reduction with sodium borohydride in phos-
phate buffer (pH = 7.4) a formation of lactone and a release of the 
drug was indeed observed. No biological data of these compounds 
has been reported yet [33]. 
5.2. Nitroaromatics As Hypoxia-Selective Delivery Agents 
Developing anticancer drugs that could be selectively activated 
under hypoxic conditions was attempted by Denny and coworkers 
who developed few nitro aromatic mustard prodrugs which in vivo 
were converted to the corresponding hydroxylamino derivatives (29 
in Fig. 28). In the hypoxic cells in malignant tumors, nitro groups 
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Fig. (28). Reduction, cyclization and releasing of aromatic mustard. 
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are reduced into amino groups to trigger cyclization and result in a 
release of these cytotoxic aromatic mustards (Fig. 28) [1, 32, 33].  
5.3. Trimethyl Lock-Based Prodrugs 
The accepted definition of the Thorpe-Ingold or gem-dialkyl ef-
fect is the increase in both rate and equilibrium constants of cycliza-
tion reactions resulting from placing groups in the linking chain. 
The effect of gem-dialkyl substitution is explained in terms of strain 
enhancement and reduced entropy of rotation in the open-chain 
moiety. It is well documented that the Thorpe-Ingold effect on the 
formation of normal rings varies considerably, and depends on both 
the type of reaction and the position of the group(s) in the chain. 
A “trimethyl lock” system has been known to facilitate lactoni-
zation reactions of o-hydroxylphenylpropionic acid and its deriva-
tives with an effective molarity of 10 [44]. These facile lactoniza-
tion reactions have been used by Borchardt and co-workers to de-
velop redox-, esterase-, [45-47] and phosphatase-sensitive prodrug 
systems [48] and an esterase sensitive cyclic prodrug system for 
peptides (Fig. 29) [49, 50]. 
The esterase-sensitive prodrug system was adjusted with anis-
idine as an amine model. The prodrug was found under all condi-
tions to degrade with half-life values of 12 minutes under exposure 
of porcine liver esterase, 54 minutes upon exposure to plasma and 
475 minutes in plasma containing diisopropylfluorophosphate [47].  
The redox sensitive prodrug concept was studied with both 
aromatic and aliphatic amines [45, 51, 52]. The reduction of qui-
none portion of prodrugs 30-32 (Fig. 29) generates the intermediate 
hydroquinone which rapidly lactonizes, yielding the corresponding 
parent drug. Following reduction to hydroquinone (X=OH) the 
half-life values of these prodrugs were found in the range 1.4 to 3.4 
minutes [45].  
The pharmaceutical properties of several drugs were improved 
by using the two-step prodrug approach based on ‘‘trimethyl lock” 
concept. For example, the “trimethyl lock” prodrug process has 
been shown to increase ganciclovir (antiviral) oral bioavailability. 
This prodrug increased oral bioavailability by four folds [53, 54]. In 
an effort to increase the oral water solubility of the anticancer agent 
paclitaxel, its phosphatase-sensitive prodrug was made by using the 
“trimethyl lock” approach. This prodrug was shown to hydrolyze 
quickly to taxol upon exposure to alkaline phosphatases (within 25 
minutes) [53, 55].   
In another study, the efficacy of daunorubicin against ovarian 
cancer was increased upon conjugation of the drug with PEG that 
functions via a trimethyl lock lactonization [53, 56]. More recently, 
Raines and co-workers designed latent fluorophores based on the 
trimethyl lock approach. These fluorophores are essential probes for 
basic research in biochemical and biological sciences [57, 58]. 
6. ENZYME MODELS 
Over the past six decades pioneer studies by Bender, Jencks, 
Bruice, Benkovic, Menger, Kirby, Walesh and others have contrib-
uted for und Understanding the most important question in bio-
chemistry “how enzymes catalyze biochemical transformations” ? 
Generally, enzymatic reactions rates are about 1010 - 1020-fold 
higher than their non-enzymatic counterparts. For example, bio-
chemical transformation catalyzed by orotidine monophosphate 
decarboxylase are enhanced by 1017-fold whereas those involving 
the enzyme cyclophilin are accelerated by only 105-fold. It is be-
lieved that the extraordinary rates enhancement achieved by en-
zymes is due to the substrate binding onto the active site of the 
enzyme [59-63]. 
The resemblance between intramolecularity and enzymes has 
encouraged scientists to design and synthesize chemical devices 
having two reactive centers that undergo intramolecular reactions. 
Unraveling the mechanisms of these intramolecular processes has 
helped in comprehending the efficient catalysis by enzymes [64-
66]. During the past sixty years proposals were emerged from trials 
to interpret variation in efficiency versus alteration in the chemical 
features in such intramolecular devices. Among those chemical 
devices or enzyme models: (1) ‘‘orbital steering’’ proposal by 
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Fig. (29). Trimethyl lock-based prodrugs. 
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Koshland which relates accelerations in intramolecularity rate with 
the attack angle of the nucleophile onto electrophile such as in the 
acid-catalyzed lactonization of hydroxy acids [67]; (2) near attack 
conformation or ‘‘proximity’’ in intramolecular reactions as sug-
gested by Bruice and illustrated in the ring-closing of di-carboxylic 
semi-esters [68-70]; (3) Cohen’s ‘‘stereopopulation control’’ pro-
posed accelerations in rate as a result of freezing a molecule into a 
productive conformation [71-73], (4) ‘‘spatiotemporal hypothesis’’ 
proposed by Menger which postulates that the interatomic distance 
between the nucleophile and electrophile is linearly correlated with 
the reaction rate of intramolecular process [74-78] and (5) proton 
transfer models advocated by Kirby on the acid-catalyzed hydroly-
sis of acetals and N-alkylmaleamic acids which attribute the en-
hancement in rates to hydrogen bonding formation in the transition 
states and their products [79-86]. 
Investigations on the role of chemical functional groups partici-
pate in intramolecular reactions have been conducted in order to 
comprehend the importance of such groups in enzyme catalysis. 
The mechanisms revealed from these studies have provided a clear 
picture on the relationship between intramolecular reactivity and 
chemical structure which consequently explains related aspects 
involving in enzyme catalysis. 
In this section, the mechanisms of a number of some enzyme 
models that were proposed to comprehend the catalysis by enzymes 
were explored using computational methods. The computational 
approach used in this study involves calculations of ground and 
transition states energies by different methods such as ab initio, 
AM1 and density functional theory (DFT), and molecular mechan-
ics (MM), and correlations between experimental and calculated 
rates. The computational methods used in this study are widely used 
due to their precise prediction results and are considered as reliable 
tools to predict potential drugs and prodrugs [87]. 
6.1. Bruice’s Enzyme Model Based on Ring-closing of Di-
carboxylic Semi-Esters  
The hydrolysis of di-carboxylic semi-esters 33-38 (Fig. 30) was 
investigated by Bruice and Pandit and their study demonstrated that 
the relative rate (krel) for 38>37>36>35>34>33. This result was 
explained on the basis that variation in rate is due to proximity fac-
tors; alkyl substituents on succinic acid derivatives affect the distri-
bution of conformations, the reactive gauche to unreactive anti 
ratio. Based on this hypothesis, they suggested that gem-dialkyl 
groups magnify the formation of the more reactive conformer. 
Thus, for cyclization to take place, both electrophile and nucleo-
phile must reside in the gauche conformation. In the reactant with-
out substituents, the electrophile and nucleophile are totally in the 
anti-conformer for overcoming steric interactions [68-70]. 
Menger and Bruice attributed the phenomenon of rate en-
hancements in intramolecularity to the important role of the prox-
imity between the two reacting centers in the reactants [68-70, 74-
78]. The “spatiotemporal” hypothesis advocated by Menger is 
summarized in an equation combining activation energy and intera-
tomic distance of the nucleophile and electrophile and based on 
that, he proposed that significant rate enhancements in enzymatic 
reactions are obtained by close proximity of the enzyme and sub-
strate reacting centers [74-78]. Differently, Bruice and Pandit have 
ascribed the rate accelerations in biotransformation catalyzed by 
enzymes to favorable “near attack conformations”. Based on this 
hypothesis, molecules reside in reactive conformations will have 
higher rates than those with unreactive conformers. Bruice’s idea 
combines both the interatomic distance between the nucleophile 
and electrophile and the angle of attack [68-70].  
Contrary to the proximity orientation proposal, some other 
chemists proposed that high rate enhancements observed in in-
tramolecular processes is due to steric factor [88, 89]. For testing 
whether this high enhancements in rate obtained in the cyclization 
of di-carboxylic semi-esters 33-38 is a result of proximity or strain 
factors, we have calculated, using DFT at B3LYP/6-31G (d,p) and 
HF/6-31G (d,p) levels, the energy profiles for the cyclization reac-
tions of 33-38. Our study revealed that the rate-limiting step is the 
collapse of the tetrahedral intermediate and not its formation (Fig. 
31). In contrast to Bruice’s and Pandit’s conclusion, our study dem-
onstrated that the rate enhancements are due to strain and not prox-
imity effects, “rotamer effect” [90].  
Further, to investigate whether the differences in rates of proc-
esses 33-38 (Fig. 30) is due to proximity or strain energy, we have 
calculated using MM2 method the strain energy values (Es) [91] for 
the entities involved in 33-38. The strain energy values were plotted 
against the experimental relative rate values (log krel) [68-70] and 
the results revealed a good correlation between both parameters 
(equations 1 and 2). No correlation was observed between log krel 
and the interatomic distance between the nucleophile and electro-
phile (rGM). This result strongly suggests that the determining factor 
for the enhancements in the ring-closing reaction rate is strain ef-
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Fig. (30). Di-carboxylic semi-esters 33-38. 
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fects and not Bruice’s near attack proximity orientation [68-70]. 
Additional support to this conclusion was evident by the strong 
correlation obtained from the plot of the activation energy values 
(?G‡H2O and ?G‡GP) for 33-38 versus both log krel and the MM2 
strain energy values, ?Es (TS - AN) (equations 3 and 4). 
1 ?G‡H2O B3LYP/6-31G (d,p) = -2.0657logkrel + 17.653 0.95 
2 ?G‡GP B3LYP/6-31G (d,p) = -1.7747logkrel + 14.729 0.90 
3 ?G‡H2O B3LYP/6-31G (d,p) = -1.0467?Es (TS - AN) + 3.262 
0.99 
4 ?G‡GP B3LYP/6-31G (d,p)  = -0.9101?Es (TS -AN) + 3.647 
0.98 
The main conclusions emerged from our computational study 
include (i) the activation energy in 33-38 is a function of ?Es, and 
no correlation was found between the ring-closing rate and the in-
teratomic distance O1-C2. (ii) The transition states of the rate-
limiting step were found to be with an open cyclic ring. This pro-
vides support to the conclusion that ?Es is the sole factor causing 
the discrepancy in rates of 33-38. (iii) Reactants having high strain 
energy values such as 38 are more reactive than the ones with less 
strain energy values, and the reaction rate is proportionally corre-
lated with the transition state and the reactant strain energies (?Es). 
(iv) The activation energy for the reaction of reactants having bulky 
substituents in their alkyl chains (strained reactants) is less than that 
of the ones without substituents (unstrained reactants) [90].  
6.2. Cohen’s Stereopopulation Control 
About five decades ago, Cohen et al. have researched the lac-
tonization reaction of a number of hydroxyhydrocinnamic acids, 
39-45 (Fig. 32). The study demonstrated reaction rates in the range 
of 1 to 1015. The discrepancy in rates for the structurally different 
hydroxyhydrocinnamic acids was attributed to the so called ‘‘stere-
opopulation control” [61-63]. Later, Cohen’s ‘‘stereopopulation 
control” theory was criticized by others who suggested that the high 
acceleration in rates determined by Cohen is due to a relief in strain 
energy upon the lactonization process and not a result of stereo-
population control of the trimethyl lock system [88-89]. 
The controversy regarding the determining factor for the sig-
nificant accelerations in the reaction rates of hydroxyhydrocinnamic 
acids 39-45 and hydroxy acids 46-50 (Fig. 32) has continued for 
many years. For the verification of whether Cohen’s stereopopula-
tion control [61-63] or the relief in strain as proposed by Wilcox 
and Winans [92] and confirmed by Houk’s calculations [88-89] is 
in fact the determining factor for the acceleration in rates, we have 
executed a comprehensive computational study using AM1 semi-
empirical, HF/6-31G(d,p) and DFT at B3LYP/6-31G(d,p) methods. 
In this study we studied the following: (1) calculations of ground 
state geometries and energies (?G˚, ?H˚ and ?S˚) of all the entities 
involved in the reactions of 39-45, (2) calculation of the rotation 
barriers of the side chain in 39-45 for determining whether the con-
formational restriction is crucial in the rate acceleration of the lac-
tonization process, (3) calculations of the activation energies (?G‡) 
for all steps involved. The calculation results revealed the follow-
ing: (1) contrary to Houk et al. [88-89] proposal, the lactonization’s 
rate-limiting step of hydroxy acids studied is the formation of the 
tetrahedral intermediate and not its dissociation (Fig. 33). The rate-
limiting step involves: (i) an attack of the hydroxyl (nucleophile) on 
the carbon of C=O (electrophile), (ii) a proton transfer from the 
ether oxygen to O- of the carboxylic group. The activation energy in 
(ii) is dependent on the structural features of the hydroxy acid and 
its value is a sum of the changes in entropy and enthalpy. Entropy 
changes are predominant in the initial stage of the approach (C-O 
distance is 4-2.5 Å) and enthalpy changes are in the approach’s 
second stage (C-O distance is 2.5-1.5 Å). For example, in systems 
41 and 42, the entropy change from the ground (C-O distance is 
around 3 Å) to the organized ground states (C-O distance is around 
2.5 Å) is less than that in 39 and 40 due to proximity. In a similar 
manner, in the second stage, the enthalpy change for 41 and 42 is 
less than that for 39 and 40 as a result of the proximity found in the 
tri-methyl lock system. In step (i), the activation energy is almost 
constant and not affected by the nature of the reactant. 
(2) The computational methods utilized in this study provide a 
tool for activation energy prediction if the attack angle and the in-
teratomic distance between the nucleophile and electrophile are 
known. Using the equation of the calculated and experimental en-
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Fig. (31). A diagram showing the suggested mechanism for the cyclization of di-carboxylic semi-esters 33-38. 
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ergy values potential hydroxy acids having high lactonization rates 
can be predicted, (3) contrary to that proposed by Wilcox and Wi-
nans [92] ground state energies alone are not sufficient to estimate 
rates, and it is a must to find a transition state along the reaction 
path to calculate its energy (barrier). 
As mentioned before, there are two different explanations for 
rate enhancements in intramolecular processes and enzymes: Men-
ger [74-78] and Bruice [68-70] proximity hypothesis and Jencks 
and others entropy driven process [88-89, 92, 93]. Our calculations 
revealed that Jencks’s entropy proposal [93] does not apply to this 
studied case, since our calculations demonstrate that there is no 
change in entropy from GSp to TS (Fig. 34) and most entropy 
changes happen during the pre-organization step. In addition, the 
calculated frequencies revealed a constant ratio of the number of 
frequencies < 1000 cm-1 to the sum of frequencies from the GSp to 
the TS (C-O distance between 2.5 - 1.5Å, X and Y in Fig. 34). Fur-
thermore, our calculations revealed that the system studied is in a 
perfect fit to the proximity proposal. The calculated ground state 
energies indicate that 41 possesses a near attack conformation 
(NAC), while 39 requires about 7 kcal/mol in order to reach the 
NAC. This difference in energy is equal to 106-fold in the rate ratio 
of 41/39. In addition, we have demonstrated that in the approach’s 
second stage the energy required for 39 to reach the transition state 
is 7 kcal/mol higher than for 41 (106-folds in 41/39 ratio rate). This 
is due to the fact that the pre-organized structure of 41 is much 
more favorable conformation for achieving efficient overlapping 
than the pre-organized conformation of 39, which was found to 
possess conformational changes during the second stage of the ap-
proach because of its high flexibility [94-96]. 
6.3. Menger’s Enzyme Model Based on Intramolecular Proton 
Transfer in Kemp’s Acid Amides 
Menger’s singularity model and spatiotemporal hypothesis pre-
dict that a good and efficient enzyme model could be made using 
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Fig. (32). Chemical structures for hydroxyhydrocinnamic acids 39-45 and 
hydroxy acids 46-50. 
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Fig. (33). Suggested mechanism for the lactonization of hydroxyhydrocinnamic acids 39-45 and hydroxy acids 46-50. 
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rigid organic moieties having the two reacting centers at or near the 
critical distance. One of the most striking enzyme models that meet 
this requirement is the intramolecular-catalyzed hydrolysis of an 
aliphatic amide (Fig. 35) [74]. Noting that an aliphatic amide is 
very difficult to be hydrolyzed (more than 10-hour reflux in con-
centrated hydrochloric acid is needed for such hydrolysis). On the 
other hand, when a carboxyl group is placed in positions 1 and 3 
diaxial to the amide, the t1/2 value for the amide cleavage is 8 min-
utes at pH 7 and 21.5 °C. Although the structure shown in Figure 
35 has two carboxyl groups, only a single carboxyl is necessary for 
achieving an enzyme-like rate enhancement.  It is worth noting that 
the reaction of this aliphatic amide occurs through the more stable 
structure B rather than structure A (Fig. 35). 
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Fig. (35). Conformations A and B for Menger’s reactive amide where B is 
presumably the most reactive conformer. 
The fundamental question of how enzyme catalysis is achieved 
is yet to be unraveled [59-65]. This kind of understanding needs a 
proven mechanism for the reaction, and a comprehensive knowl-
edge on the energy components, enthalpy and entropy of all entities 
along the reaction profile [64-65]. One prominent example of en-
zyme models that were advocated for understanding enzyme cataly-
sis is the breakdown of Kemp’s di-acid amide 51 that was synthe-
sized by Menger and Ladika to explore the mechanism by which 
chymotrypsin enzyme catalyzes biotransformation processes [74]. 
Enzymes such as chymotrypsin catalyze the cleavage of peptide 
bonds via a nucleophilic attack of serine 195 of the enzyme onto the 
amide unreactive carbonyl group resulting in covalently linked 
substrate-enzyme intermediate. It was suggested that this break-
down of the peptide bond with chymotrypsin enzyme involves two 
stages: ‘‘burst’’ and ‘‘ping-pong’’. In other words, this enzymatic 
reaction occurs in two steps; an acylation of the peptide which in-
volves a transfer of a proton to yield an acyl-enzyme intermediate 
which subsequently followed by deacylation to allow the enzyme to 
be freed to its original state [97, 98]. In the chemistry laboratory, 
peptide cleavage rate is very slow; at pH 7 and room temperature, 
the t1/2 is around 500 years, with the absence of strong acid [99, 
100], whereas in the small intestines (pH 6.8), all proteins are hy-
drolyzed rapidly. This acceleration in rate is as a result of pepti-
dases catalysis through a proton transfer process [101].  
HF/6-31G (d,p) and DFT at B3LYP/6-31G (d,p) level thermo-
dynamics and kinetics calculations for the amide breakdown of 
Menger’s enzyme model, 51-61 (Fig. 36) were conducted to com-
prehend the significant rate acceleration brought about when these 
amides stand in neutral aqueous solution at ambient temperature. 
The aims of our computational study were: (1) to determine 
whether those amides undergo rapid cleavage as a result of a proton 
transfer reaction driven by proximity of the nucleophile (O6, see 
Scheme 1) to the electrophile (H5, see Scheme 1), as proposed by 
Menger [74], or whether it is a result of pseudoallylic (pseudo-A) 
strain relief upon the breakdown of the distorted amide bond to 
unstrained tetrahedral intermediate that is evolved upon the carbox-
ylic oxygen approach (O4, see Scheme 1) towards the amide car-
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Fig. (34). Suggested mechanism for the approach of the hydroxyl O to the carboxylic C in the lactonization of hydroxy acids. X and Y are the reactive centers. 
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bonyl carbon (C7, see Scheme 1), as was suggested by Curran and 
others [102, 103]. 
The mechanistic study results illustrated in Figure 37 revealed 
the following: (1) The barriers for the cleavage of amides 51- 61 at 
a pH range where the carboxylic group is in its free acid form (un-
ionized) are much smaller than that through a proton transfer (route 
b) from the carboxylic oxygen onto the amidic carbonyl carbon 
(route a). For example, the B3LYP/6-31G (d,p) calculated activa-
tion energy in the gas phase for the hydrolysis of amide 51 via a 
proton transfer (route b) is 45.18 kcal/mol less than that via route a. 
(2) The HF and DFT calculated activation energy values for the 
cleavage reactions of amides 51 and 52 are almost the same. This 
result revealed that the presence of only one carboxylic group (am-
ide 52) is necessary for achieving the same enhancement as for the 
reaction of amide 51. The calculation results are in agreement with 
Menger’s experimental results [74]. (3) The calculated activation 
energy in water for the breakdown of amide 53 was ~3 kcal/mol 
less than that of amide 51. This slight difference in energy might be 
due to the difference in the interatomic distances 51 and 53; H5—
O6 distance (Scheme 1) in 51 is 2.9 Å and in 53 is 3.0 Å. This is in 
agreement with the‘‘spatiotemporal hypothesis” and our calcula-
tions of other enzymes models [104-109]. 
In addition, the DFT calculations for the breakdown of Kemp’s 
mono- and di-acid amides 51-61 demonstrate that a proton transfer 
from the carboxyl into the amide carbonyl oxygen is the rate limit-
ing step in the acylolysis. It is suggested that enhancements in rate 
are dependent on r and ? (Scheme 1). In addition, it was found that 
the activation energy (?G‡) is strongly correlated with r2 x sin (180 
- ?). Further, contrary to previous reports the pseudoallylic factor 
has a negligible contribution if any to Kemp’s triacid tertiary am-
ides cleavage rates. Furthermore, our calculations propose a change 
in the mechanism when changing the reaction pH. Therefore, pepti-
dase enzymes are too reactive at neutral pH while their efficiency is 
drastically decreased at basic pHs. 
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Scheme 1. Schematic representation for the cleavage of 51-61 showing the 
interatomic distance between the reacting centers (r) and the attack angle 
(?).  
6.4. Kirby’s Enzyme Model - Acid-Catalyzed Hydrolysis of N-
alkylmaleamic Acids 
Among the most common biotransformation that enzymes cata-
lyze is the proton transfer reactions catalyzed by acid or base such 
as in the cases of triose phosphate isomerase and ?5-3-ketosteroid 
isomerase. The findings that enzyme substrate interactions occur 
between functional groups held closely encouraged scientists to 
utilize intramolecularity in modeling the extremely high efficiency 
of enzymes. 
Kirby et al. have studied the acid catalyzed hydrolysis of  
N-alkylmaleamic acids 62-68 to their corresponding maleamic ac-
ids and amines (Fig. 38). The study found that the reaction is re-
markably sensitive to the nature of the alkyl groups on the alkene 
bond. In addition, it demonstrated that the range of the hydrolysis 
rates for the studied dialkyl-N-methylmaleamic is more than  
1010 s-1, and the “effective concentration” of the carboxyl group of 
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Fig. (36). Chemical structures of aliphatic amides 51-61. 
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the most reactive amide, dimethyl-N-n-propylmaleamic acid, is 
greater than 1010 M. In addition, the study revealed that dimethyl-
N-n-propylmaleamic acid underwent cleavage to the more stable 
dimethylmaleic anhydride in less than 1s at 39 °C < pH 3 [80]. In 
addition, the study by Kirby revealed that the neighboring carboxyl 
group is involved in the intramolecular nucleophilic catalysis which 
causes the breakdown of the amide bond. Moreover, based on that 
the isomaleimide was formed as intermediate and totally was con-
verted to into N-methylmaleamic acid (Fig. 39); Kirby concluded 
that the collapse of the tetrahedral intermediate is the rate-limiting 
step of the reaction [80]. On the other hand, Kluger et al. investi-
gated the intramolecular hydrolysis mechanism of a number of N-
alkylmaleamic acids having alkyl amine moieties with different 
basicities [110]. Their study demonstrated that the factor affecting 
the rate-limiting step is the leaving group basicity of the leaving 
group and the solution acidity.  In the early nineties, Katagi has 
calculated the reaction mechanism using AM1 semiempirical 
method and based on his study he concluded that the tetrahedral 
intermediate formation is the rate-limiting step and not its collapse 
[111]. For unraveling the factors playing dominant role in proton 
transfer processes we have computationally studied the hydrolysis 
of Kirby’s N-alkylmaleamic acids, 62-68. 
The goals of our computational study were to: (i) examine if the 
rate-limiting step in 62-68 is due to the tetrahedral intermediate 
association or collapse, and to determine the factors responsible for 
the extremely high rates achieved in the acid-catalyzed hydrolysis 
of 63 and 66, (ii) assign the structural features associated with the 
significant reactivity in the hydrolysis for considering such factors 
when investigating biotransformation catalyzed by enzymes.  
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Fig. (39). Conversion of isomaleimide to N-methylmaleamic acid. 
Using DFT calculation methods at B3LYP/6-31G (d,p), 
B3LYP/311+G (d,p) levels and hybrid GGA (MPW1k) we have 
computed the acid-catalyzed hydrolysis of maleamic (4-amino-4-
oxo-2-butenoic) acids (Kirby’s N-alkylmaleamic acids) 62-68 (Fig. 
38) and the calculations confirmed that the reaction proceeds in 
three steps: (a) a transfer of a proton from the carboxylic acid moi-
ety to the neighboring amide carbonyl followed by, (b) an attack of 
the carboxylate anion onto the protonated amide carbonyl carbon 
and the final step of the reaction involves (c) the tetrahedral inter-
mediate collapse to provide products (Fig. 40). In addition, the cal-
culation results revealed that reaction medium is a crucial factor in 
determining the rate-limiting step of the reaction. The calculations 
in the gas phase revealed that the rate-limiting step was the tetrahe-
dral intermediate formation, whereas the calculations in water 
demonstrated that the tetrahedral intermediate collapse was the rate-
limiting step. In addition, when CH3NH2 in 62-68 was replaced 
with an amine having a low pKa the rate-limiting step was the 
formation of the tetrahedral intermediate, such as in the case where 
CH3NH2 was replaced with CF3NH2 (see Fig. 40).  
Furthermore, the calculation results demonstrated that the hy-
drolysis rate is dependent on the substituents on the C=C bond. It 
was found that the rate of hydrolysis is a function of the tetrahedral 
intermediate or product strain energies. High rates were found for 
systems with unstrained tetrahedral intermediates or products 
whereas systems with strained intermediates or products were asso-
ciated with low hydrolysis rates [112-115].  
The fact that the calculated EM values were found to linearly 
correlate with the experimental EM values establishes a credibility 
to use DFT methods for calculating similar systems to that studied 
herein [112-115].  
6.5. Kirby’s Enzyme Model Based on Intramolecular Proton 
Transfer in Acetals  
Another important enzyme model that was computationally in-
vestigated by us is Kirby’s intramolecular proton transfer in acetals. 
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Fig. (37). Suggested mechanism for the hydrolysis of aliphatic amides 51-
61. 
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The efficiency of proton transfer in Kirby’s enzyme models 69-76 
(Figs. 41-43) were studied by computing the thermodynamic and 
kinetic parameters for all entities involved in the reaction [65-66, 
79, 81-86, 116-120].  
The aim of this computational investigation was to: (a) deter-
mine the nature of the driving force(s) for the intramolecular gen-
eral acid catalysis (IGAC) in 69-76 (Figs. 41 and 42), and (b) to 
assign the hydrogen bonding along the reaction and to determine 
their role in the process.  
Using HF/6-31G (d,p) and DFT B3LYP/6-31G (d,p) methods 
the kinetic and thermodynamic parameters for the IGAC in proc-
esses 69-76 (Figs. 41 and 42) were calculated. 77 and 78 were cho-
sen to be used as intermolecular proton transfer processes for calcu-
lating the effective molarities (EM) of the intramolecular processes 
69-72 and 73-76, respectively. Process 79 was studied to represent 
a proton transfer process driven by “classical” general catalysis 
(GAC) for comparisons with IGAC.  The calculations revealed that 
the following structural features should be included in a system for 
an efficient proton transfer: (i) a short interatomic distance between 
the nucleophile and electrophile (rGM, see Scheme 2) in the GM 
which results in strong intramolecular hydrogen bonding, and (ii) 
the attack angle ? (see Scheme 2) in the GM should be close to 
180°. Among systems 69-72 that were investigated, systems 69 and 
72 were the most efficient since both comply with the two require-
ments (?= 170° and rGM = 1.7 Å). System 74 is the most inefficient 
since the attack angle and interatomic distance are quite different 
from the optimal values, ?=48° and rGM = 3.7 Å. 
In order to test if the reaction mechanism for systems such as 69 
occurs via efficient IGAC or GAC calculations for processes 77 and 
79 were conducted; where process 77 involves intermolecular pro-
ton transfer from acetic acid to an acetal, and process 79 is similar 
to that of 69 where acetic acid was replaced with a water molecule 
as a proton donor to the acetal (Fig. 43). When the calculated DFT 
activation energies for processes 77 and 79 were compared with 
that of 69 it was found that IGAC for 69is much more efficient than 
that of 77 and 79 by GAC (?G‡ value for 69 is 24.15 kcal/mol, and 
for 77 and 79 are 38.55 kcal/mol and 53.14 kcal/mol, respectively). 
This result confirms that the proton that catalyzes the breakdown of 
the acetal group of 69 must be provided by the carboxyl group. 
Thus the mechanism in systems such as 69 is via IGAC and not 
GAC [116-120]. 
The EM values obtained indicates that 69 and 72 are the most 
efficient processes among 69-76 (log EM 10-13) and among the 
least efficient processes are 71, 75 and 76 with log EM <1. In addi-
tion, the calculations demonstrated that the proton transfer rate in 
systems 69-76 is largely affected by geometrical parameters, par-
ticularly rGM, and ?. The following requirements are necessary to 
achieve efficient intramolecular proton transfer: (1) small values of 
rGM which could result in obtaining strong intramolecular hydrogen 
bonds, and (2) ?GM values at or near 180˚ for maximizing orbitals 
overlapping. The equation ?G‡ vs. r2GM x (1 + sin (180 - ?) which 
correlates calculated activation energy values with geometrical 
parameters establishes an efficient and fruitful tool for the predic-
tion  of  reactions  rates. The equation slope value is an indication to  
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Fig. (40). Suggested mechanism for the hydrolysis of 62-68. 
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Scheme 41. Chemical structures of 69-72. 
 
Fig. (42). Chemical structures of 73-76. 
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Fig. (43). Chemical structures of 77-79. 
 
Scheme 2. Schematic representation for the cleavage of 69-72 and 73-76 showing the interatomic distance between the two reacting centers (rGM) and the attack 
angle (?). 
 
the mode by which the two reactive centers orchestrate in an in-
tramolecular process. In extrapolation of the calculation results to 
enzymes we suggest that enzymes are very efficient in catalysis due 
to their ability to hold the reacting centers in a range of contact 
distances at the enzyme’s active site [64-66, 74-79, 81-86, 116-
120]. 
7. NEW PRODRUGS BASED ON THE ABOVE DISCUSSED 
ENZYME MODELS [121-165] 
The above mentioned computational studies on intramolecular-
ity have demonstrated that these chemical devices (enzyme models) 
have the potential to be utilized as efficient prodrug linkers to be 
attached to parent active drugs and upon in vivo administration they 
will release the active drugs in a programmable manner by a chemi-
cal and not enzymatic process.  
For instance, the aza-nucleoside azacitidine is administered by 
SC injection and reached peak plasma concentration immediately 
after administration. If a sustained release prodrug can be synthe-
sized, then Cmax associated adverse effects may be eliminated and 
the drug’s duration of action will be longer resulting in potentially 
more effective clinical profile. Another example of the same family, 
decitabine is given by continuous IV infusion. If a prodrug that can 
be degraded in programmable manner can be provided by SC injec-
tion this could provide a very good option for MDS maintenance 
patients on treatment [121, 122].  
Improvement of the pharmacokinetic properties and hence the 
effectiveness of the marketed aza-nucleosides such as azacitidine, 
cytarabine and decitabine may enhance the permeation of the the 
aza-nucleoside through various administration routes, such as SC 
injection route. This can be obtained by using the prodrug approach 
in which the aza nucleoside drug is attached to a carrier moiety to 
yield a chemical device capable of partitioning through the mem-
brane tissues and releasing the aza nucleoside drug in a controlled 
manner.  
Statins are a family of pharmaceuticals used for lowering cho-
lesterol levels in the blood. They are commonly applied for the 
reduction of cardiovascular-related morbidity and mortality in pa-
tients with or at risk of coronary heart diseases. In the long and 
complex biosynthesis of cholesterol in humans, the first and rate-
determining step is 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase which catalyzes the conversion of HMG-
CoA to mevalonic acid. Clinical studies have demonstrated that 
statins are potent and competitive inhibitors of HMG-CoA reduc-
tase for cholesterol synthesis, thereby limiting the hepatic produc-
tion of low-density lipoprotein (LDL). The absorption of satins 
such as simvastatin, atorvastatin and rosuvastatin is very rapid and 
reaches peak plasma concentration within 4 hours after administra-
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tion, and all of statins have the liver as their target organ [123, 124]. 
Statins in general have a relatively low bioavailability mostly due to 
the extensive first pass effect and/or bad solubility. 
Increasing the usefulness of therapeutics can be achieved utiliz-
ing the prodrug approach strategy, because one can optimize any of 
the absorption, distribution, metabolism and elimination (ADME) 
properties of potential medicines to reach a satisfactory bioavail-
ability. Simvastatin solubility is the limiting factor for its bioavail-
ability as a result of slow tissue penetration therefore, it undergoes a 
significant first pass effect; hence, improving its solubility and its 
dissolution rate is a crucial for enhancing its bioavailability.  Thus, 
development of more hydrophilic prodrugs that have the potential 
to liberate the active parent drug in physiological environments is a 
significant challenge.  
Aza-nucleosides prodrugs for myelodysplastic syndromes [125-
132] and statins prodrugs to reduce cholesterol levels in the blood 
circulation [133-137] were designed and made utilizing the proton 
transfer reaction in Kirby’s acetals. In these examples, the linker 
was covalently bonded to the hydroxyl group of the parent drug 
such that upon exposure to stomach, intestine, or blood circulation 
the prodrug degrades in a rate that is only dependent on the struc-
tural features of the linker (Kirby’s acetal). Kinetics studies are 
underway to determine the interconversion rates of the synthesized 
prodrugs into their parent active drugs in different physiologic me-
dia and plasma [125-137]. 
On the other hand, tranexamic acid, a synthetic lysine amino 
acid derivative. was synthesized to reduce and prevent hemorrhage 
in hemophilia patients and decrease the frequency for replacement 
therapy during tooth extraction. In addition, it is used in excessive 
bleeding conditions. The availability of blood and fluid replacement 
in most of third world countries is scarce. Among the approaches to 
decrease the risk of maternal hemorrhage is to improve the avail-
ability of blood and fluid replacement. Another approach is to de-
crease the likelihood of maternal hemorrhage. Moreover, the above 
mentioned treatments are intended for I.V. administration which 
may not be a viable option in the third world counties. Hence, the 
possibility of using a cheaper oral treatment will be better suited for 
such circumstances [138, 139]. 
The oral bioavailability of the amino acid tranexamic acid is 
relatively low due to its ionization in physiologic environments 
which results in poor absorption through membranes tissues.  The 
log P (partition coefficient) value for tranexamic acid is -1.6. Thus, 
it is a necessity to design and synthesis more lipophilic prodrugs of 
tranexamic acid that can improve the permeation of the drug and 
consequently its oral bioavailability. In addition, tranexamic acid 
prodrugs with certain linkers can provide a chemical device which 
upon exposure to physiologic environment is able to release the 
active parent drug in a slow release manner which might result in 
better clinical outcome, more convenient dosing regimens and po-
tentially less adverse effects than the tranexamic acid. 
Another important drug that suffers poor oral bioavailability is 
acyclovir, a synthetic acyclic purine nucleoside derivative that is 
the first anti-viral medicine to be licensed for the treatment and 
prevention for viral infections result from herpes simplex (HSV), 
varicella zoster (chicken pox) and herpes zoster (shingles). The 
water solubility of acyclovir is very low and has a poor oral 
bioavailability of 10-20%; therefore, I.V. administration is a must if 
large doses are required. Aciclovir reaches a peak plasma concen-
tration after 1-2 hours from its administration. It has a high distribu-
tion rate with about 30% is protein-bound in plasma. Aciclovir 
elimination half-life is about 3 hours. It is renally excreted by both 
glomerular filtration and tubular secretion [140, 141]. 
Similarly, a number of tranexamic acid prodrugs for the treat-
ment of bleeding conditions [142] and acyclovir prodrugs as anti-
viral drug for the treatment of Herpes Simplex [113] were designed 
and synthesized using Kirby’s N-alkylmaleamic acids enzyme 
model as a linker. 
In vitro kinetic studied on these prodrugs have shown that the 
interconversion rate of a prodrug can be programmed according to 
the nature of the linker (Kirby’s N-alkylmaleamic acid). Strained 
linkers provided interconversions with higher rates than those with 
unstrained linkers. 
Another example by which the prodrug approach utilizing in-
tramolecularity has achieved successes is the design and synthesis 
of dopamine prodrugs. As it is well known, the death of dopamine 
neurons in the nigrostriatal pathway results in shortage of dopamine 
which causes Parkinson's disease. This disease is accompanied by a 
loss of the ability to execute smooth and controlled movements. 
Dopamine can be provided as a drug that acts on the sympathetic 
nervous system to produce effects such as increased heart rate and 
blood pressure. However, because dopamine cannot cross the 
blood-brain barrier (BBB), when administered as a drug it does not 
directly affect the central nervous system (CNS). For increasing the 
concentrations of dopamine in the brains of Parkinson's disease 
patients and dopa-responsive dystonia, levodopa (L-DOPA), the 
precursor of dopamine, is administered since it can cross the blood-
brain barrier. 
Levodopa is usually is given in combination with an inhibitor of 
peripheral decarboxylation (DDC, dopa decarboxylase), such as 
carbidopa or benserazide. Although this combination has shown 
some enhancement in the bioavailability of dopamine, further modi-
fication on dopamine structural features still to be made in order to 
provide a medication with very effective clinical profile [143, 144]. 
Based on the computational calculations done on the previously 
mentioned enzyme models, prodrugs of dopamine to treat Parkin-
son’s disease [145] were made utilizing Menger’s Kemp acid en-
zyme model as the prodrug promoiety. In addition, dimethyl fu-
marate prodrugs for psoriasis treatment were designed, synthesized 
and work in progress to determine their in vitro and in vivo kinetic 
parameters [146]. It is worth noting that high oral doses of dimethyl 
fumarate is needed to efficiently treat psoriasis, however, obtaining 
a chemical device that can release the active drug in a sustained 
release manner will be a good option to eliminate the adverse side 
effects associated with the treatment of dimethyl fumarate in high 
dosing and improve the therapeutic profile of the drug. 
Following this approach we have succeeded to make bitterless 
prodrugs to replace their corresponding bitter active drugs. Exam-
ples for this approach include antibacterial drugs, amoxicillin, 
cephalexin and cefuroxime, and the pain killer, paracetamol 
[147,148]. The role of the linker in these prodrugs examples is to 
block the amine or hydroxyl group responsible for bitter sensation. 
In the antibacterial prodrugs the amine group is replaced with an 
amide, thus inhibiting any interaction between the drug and the 
bitter taste receptor.  
In the case of paracetamol prodrugs the hydroxyl group on the 
phenyl ring of paracetamol is believed to be the main contributor 
for the bitter sensation of the drug presumably through hydrogen 
bonds between the phenolic hydroxyl and the bitter taste receptor’s 
active site. Masking hydroxyl in paracetamol with a linker is ex-
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pected to prevent any binding between paracetamol and the recep-
tor’s active site [147-165].   
CONCLUSION  
In order to avoid the disadvantages associated with the use of 
enzymatic prodrug activation strategy, intramolecular activated 
prodrug strategy has been developed. Cyclization activated pro-
drugs are widely used in ester and amide prodrugs. Ester prodrugs 
are derived from carboxyl or hydroxyl containing drugs, including 
pilocarpine acid double esters that are activated by base-catalyzed 
lactonization, paracetamol dipeptide esters that intramolecularly 
release diketopiprazine and paracetamol in vitro, ester prodrugs of 
propranolol that were developed to increase parent drug bioavail-
ability and amino esters, an important class of prodrugs in which 
the release rate of the parent drug is dependent on steric effect.  
Amide prodrugs were also designed to improve physicochemi-
cal characteristics of amine drugs, these prodrugs include carbamate 
prodrugs, quinone propionic acid prodrugs, doxorubicin hydrazone 
and hydrazine carboxylate prodrugs, prednisolone 21-
hemisuccinate ?-cyclodextrin prodrugs and HIV-protease inhibitor 
prodrugs that were designed to increase water solubility, and to be 
intramolecularly converted into their active drugs. 
Furthermore, ab initio and DFT have proven to be effective in 
predicting energies and release rates of prodrugs to their parent 
drugs. Using this approach, tranexamic acid, atenolol, statins, phen-
ylephrine, atovaquone, aza-nucleoside, aciclovir, cefuroxime and 
paracetamol prodrugs were designed, synthesized and their in vitro 
kinetics were studied. 
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